MAPT and Alzheimer disease: In a subset of 188 participants who had measurements for both plasma VWF and CSF AD biomarkers (i.e., Aβ42, total tau, and p-tau181 levels) at baseline, Pearson’s correlation tests were performed to examine the associations of plasma VWF levels with CSF Aβ42, total tau, and p-tau181 levels.